Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor.
Alexander T BakerRosie M MundyJames A DaviesPierre J RizkallahAlan L ParkerPublished in: Science advances (2019)
Adenoviruses are clinically important agents. They cause respiratory distress, gastroenteritis, and epidemic keratoconjunctivitis. As non-enveloped, double-stranded DNA viruses, they are easily manipulated, making them popular vectors for therapeutic applications, including vaccines. Species D adenovirus type 26 (HAdV-D26) is both a cause of EKC and other diseases and a promising vaccine vector. HAdV-D26-derived vaccines are under investigation as protective platforms against HIV, Zika, and respiratory syncytial virus infections and are in phase 3 clinical trials for Ebola. We recently demonstrated that HAdV-D26 does not use CD46 or Desmoglein-2 as entry receptors, while the putative interaction with coxsackie and adenovirus receptor is low affinity and unlikely to represent the primary cell receptor. Here, we establish sialic acid as a primary entry receptor used by HAdV-D26. We demonstrate that removal of cell surface sialic acid inhibits HAdV-D26 infection, and provide a high-resolution crystal structure of HAdV-D26 fiber-knob in complex with sialic acid.
Keyphrases
- cell surface
- clinical trial
- high resolution
- respiratory syncytial virus
- binding protein
- single cell
- gene therapy
- endothelial cells
- randomized controlled trial
- stem cells
- zika virus
- mass spectrometry
- hiv infected
- cell therapy
- human immunodeficiency virus
- hiv testing
- bone marrow
- open label
- men who have sex with men
- study protocol
- tandem mass spectrometry
- phase iii
- double blind